Sellas Positive Recommendation from Independent Data Monitoring Committee of AML Phase 3

–  The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications –

–  No Safety or Futility Concerns Were Raised Based on theEfficacy and Safety Assessment of All REGAL Patients  –

–  Interim Analysis Anticipated by Q4 2024  –

https://www.biospace.com/article/releases/sellas-life-sciences-announces-positive-recommendation-from-the-independent-data-monitoring-committee-of-the-phase-3-regal-trial-in-acute-myeloid-leukemia/